Table 2 Susceptibility of CRE based on testing methods in this study (N = 75)
Testing methoda | Testing results (%, [no. of strains]) | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
CIP | LEV | GEN | AMK | |||||||||
S | I | R | S | I | R | S | I | R | S | I | R | |
ADM | 37.3% (28) | 9.3% (7) | 53.3% (40) | 52.0% (39) | 10.7% (8) | 37.3% (28) | 17.3% (13) | 1.3% (1) | 81.3% (61) | 74.7% (56) | 10.7% (8) | 14.7%(11) |
Vitek-2 | 40.0% (30) | 8.0% (6) | 52.0% (39) | 52.0% (39) | 1.3% (1) | 46.7% (35) | 20.0% (15) | 2.7% (2) | 77.3% (58) | 86.7% (65) | 0 | 13.3%(10) |
Phoenix | 33.3% (25) | 8.0% (6) | 53.3% (40) | 42.7% (32) | 8.0% (6) | 48.0% (36) | 18.7% (14) | 4.0% (3) | 77.3% (58) | 84.0% (63) | 1.3% (1) | 14.7% (11) |
Microscan | 29.3% (22) | 8.0% (6) | 62.7% (47) | 45.3% (34) | 6.7% (5) | 48.0% (36) | 22.7% (17) | 4.0% (3) | 73.3% (55) | 80.0% (60) | 5.3% (4) | 14.7% (11) |